Adocia

Report Publication Announcement • Feb 9, 2018

PRESS RELEASE

Adocia to Present at the 2018 BIO CEO & Investor Conference

Lyon, France, February 9, 2018 – 6pm CEST – Adocia (Euronext Paris: FR0011184241- ADOC), the clinical biopharmaceutical company focused on developing innovative formulations of approved proteins for the treatment of diabetes and other metabolic diseases, announced today that Gerard Soula, Chairman and Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference being held on February 12-13, 2018 at the New York Marriott Marquis in New York City.

Dr. Soula will deliver the Company's presentation focused on Adocia's diverse pipeline and development strategy.

Details for the presentation are below:

Event: 2018 BIO CEO & Investor Conference Date: Tuesday, February 13, 2018 Time: 10:30 am ET Presentation Room: Odets Room

The management team including Mr. Soula and Dr. Stanislav Glezer, Adocia's Chief Medical Officer, will be available for one-on-one meetings. To arrange a meeting with management, please contact Tram Bui at tbui@theruthgroup.com or visit the BIO CEO One-on-One Partnering webpage to schedule a one-on-one directly.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides. Adocia's portfolio of injectable treatments for diabetes, featuring five clinical-stage products and four preclinical products, is among the largest and most differentiated of the industry. Adocia expanded its portfolio to develop treatments for obesity and short bowel syndrome.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application to address specific patient needs.

Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). An aqueous formulation of human glucagon (BioChaperone Human Glucagon) successfully completed a Phase 1 trial. Adocia also develops a prandial combination of human insulin with amylin analog pramlintide

(BioChaperone Pramlintide hIns), two combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), a ready-to-use aqueous formulation of teduglutide (BioChaperone Teduglutide) and a ready-to-use combination of glucagon and exenatide (BioChaperone Glucagon Exenatide), all of which are in preclinical development.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

Adocia	Adocia	Press	Relations	Adocia Investor Relations
Gérard Soula	Europe			USA
Chairman and CEO	MC Services AG			The Ruth Group
contactinvestisseurs@adocia.com	Raimund Gabriel			Tram Bui
Ph. : +33 4 72 610 610		adocia@mc-services.eu		tbui@theruthgroup.com
		Ph.: +49 89 210 228 0		Ph. : +1 646 536 7035

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forwardlooking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Reference Document filed with the French Autorité des marchés financiers on April 11, 2017 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.